SCHEMBL4449892

SCHEMBL4449892

CC(C)(C)OC(=O)N1CC(Oc2cccc(F)c2)C[C@H]1C(=O)N1CCCN(C2CCC2)CC1

nearest known ligand 0.83

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 20/20 0.83
KCNH2 Q12809 5/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4449797 1.00 HRH3 (0.83) HRH3KCNH2
SCHEMBL4448740 1.00 HRH3 (0.83) HRH3KCNH2
SCHEMBL4448594 1.00 HRH3 (0.83) HRH3KCNH2
SCHEMBL4447024 1.00 HRH3 (0.83) HRH3KCNH2
SCHEMBL4446989 0.91 HRH3 (0.71) HRH3KCNH2
SCHEMBL4445047 0.91 HRH3 (0.69) HRH3KCNH2
SCHEMBL4321177 0.91 HRH3 (1.00) HRH3KCNH2
SCHEMBL4449761 0.90 HRH3 (0.68) HRH3KCNH2
SCHEMBL4452088 0.90 HRH3 (0.68) HRH3KCNH2
SCHEMBL4449903 0.90 HRH3 (0.82) HRH3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236792-B2 Substituted pyrrolidine amides as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA NV (BE) 2012-08-07 US claimed
US-20090291903-A1 SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-11-26 US claimed
US-8236792-B2 Substituted pyrrolidine amides as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA NV (BE) 2012-08-07 US disclosed
US-8236792-B2 Substituted pyrrolidine amides as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA NV (BE) 2012-08-07 US disclosed
US-8236792-B2 Substituted pyrrolidine amides as modulators of the histamine H3 receptor JANSSEN PHARMACEUTICA NV (BE) 2012-08-07 US disclosed
WO-2009143153-A1 SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2009-11-26 WO disclosed
US-20090291903-A1 SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-11-26 US disclosed
US-20090291903-A1 SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-11-26 US disclosed
US-20090291903-A1 SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291903-A1 SUBSTITUTED PYRROLIDINE AMIDES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH2 HRH3 1/4885KCNH2 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.